As spot­light trains on bio­phar­ma di­ver­si­ty, most com­pa­nies kept their C-suites ex­act­ly the same in 2020 — re­port

The past year has cast a harsh spot­light on the bio­phar­ma in­dus­try’s lack of di­ver­si­ty. And though most com­pa­nies list di­ver­si­ty and in­clu­sion as one of their key val­ues, a whop­ping 67% of com­pa­nies saw lit­tle or no change in rep­re­sen­ta­tion by race or eth­nic­i­ty at the ex­ec­u­tive lev­el, ac­cord­ing to a re­cent BIO sur­vey.

As part of its sec­ond an­nu­al di­ver­si­ty re­port, BIO part­nered with Co­qual (for­mer­ly known as Cen­ter for Tal­ent In­no­va­tion) to sur­vey 100 com­pa­nies from Oc­to­ber to De­cem­ber 2020. They re­ceived or­ga­ni­za­tion-lev­el di­ver­si­ty da­ta from 18 com­pa­nies, and ex­ec­u­tive-lev­el di­ver­si­ty da­ta from 16. Sev­en­ty per­cent of re­spon­dents list­ed D&I as one of their stat­ed val­ues, BIO said. But on­ly 13% ac­tu­al­ly in­creased rep­re­sen­ta­tion for ex­ec­u­tives of col­or by at least 5%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.